Moderna has limited upside: Barclays
Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...
Investor's Business Daily on MSN12h
Is Moderna Stock A Buy As Its CEO Fends Off RFK Jr. Concerns?
Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?
Texas Department of State Health Services cancels immunization conference amid CDC uncertainty
The Texas Department of State Health Services canceled its biennial immunization conference amid uncertainty over CDC ...
Investor's Business Daily on MSN4d
Moderna Adds Onto Its 94% Dive With Light Fourth-Quarter Profit
Covid vaccine maker Moderna posted a mixed fourth-quarter report Friday and Moderna stock skidded in early action.
STAT4d
The view from overseas on tumult in U.S. science
Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today ...
Investing4d
Moderna shares fall as Q4 loss exceeds estimates
The vaccine maker posted a loss of $2.91 per share for the quarter, exceeding analysts' estimates of a $2.73 per share loss.
Moderna posts bigger loss than expected as vaccine maker scales down manufacturing
Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...
Respiratory Syncytial Virus Therapeutics Market to Hit USD 4.64 Billion by 2032, Growing at a 14.5% CAGR – SNS Insider
Therapeutics Market Growth is Driven by Increased Awareness of RSV’s Health Risks and The Development of Advanced Treatment Options.Pune, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Respiratory Syncytial Virus ...